Neurological complications of psychiatric drugs: Clinical features and management

Human Psychopharmacology

Volumn 23, Issue SUPPL. 1, 2008, Pages 15-26

  Haddad, Peter M ^a,b   Dursun, Serdar M ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antidepressants; Antipsychotics; Extrapyramidal symptoms; Neuroleptic malignant syndrome; Seizures; Serotonin toxicity

Indexed keywords

AMANTADINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DULOXETINE; FLUOXETINE; HALOPERIDOL; LITHIUM; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGITATION; AKATHISIA; AUTONOMIC DYSFUNCTION; BRADYKINESIA; CATATONIA; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CLONUS; COHORT ANALYSIS; CONFUSION; CONSCIOUSNESS LEVEL; CONSTIPATION; DELIRIUM; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG POTENCY; DRUG RECHALLENGE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; ELDERLY CARE; EXCITEMENT; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEAT STROKE; HIGH RISK POPULATION; HUMAN; HYPERREFLEXIA; HYPERSALIVATION; LOW DRUG DOSE; MANIA; MENTAL DISEASE; MENTAL HEALTH; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; NEUROTRANSMISSION; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCHIZOPHRENIA; SEBORRHEA; SEIZURE; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SIDE EFFECT; SUDDEN DEATH; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TREMOR; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MANAGEMENT; DYSKINESIA, DRUG-INDUCED; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES;

EID: 38649104884     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.918     Document Type: Review

References (99)

1. Adityanjee, Estrera AB. 1996. Successful treatment of tardive dystonia with clozapine. Biol Psychiatry 39: 1064-1065.
2. Adityanjee, Sajatovic M, Munshi KR. 2005. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 28 (4): 197-204.
3. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Association: Washington DC.
4. American Psychiatric Association. 1997. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia. Am J Psychiatry 154 (suppl. 4): 1-63.
5. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. 2004. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65 (4): 464-470.
6. Andersen H, Kristiansen ES. 1959. Tofranil treatment of endogenous depressions. Acta Psychiatr Scand 34: 387-397.
7. Aravantis LA, Miller BG, The Seroquel Trial 13 Study Group. 1997. Multiple fixed doses of seroquel in patients with acute exacerbations of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-246.
8. Ashton H. 2004. Benzodiazepine dependence (Chapter 13). In Adverse Syndromes and Psychiatric Drugs, Haddad P, Dursun S, Deakin B (eds). Oxford University Press: Oxford; 239-259.
9. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J. 2003. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 7 (13): 1-193.
10. Barnes TRE, Braude WM. 1985. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42: 874-878.
11. Borison RL, Diamond BI, Sinha D, Gupta RP, Prince Ajiboye PA. 1998. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24: 260-263.
12. Buhrich N, Weller A, Kevans P. 2000. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatr Serv 51 (7): 928-929.
13. Burke RE, Fahn S, Jankovic J, et al. 1982. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32 (12): 1335-1346.
14. Calabrese JR, Keck PE, Jr, Macfadden W, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162 (7): 1351-1360.
15. Caroff SN. 1980. The neuroleptic malignant syndrome. J Clin Psychiatry 41 (3): 79-83.
16. Caroff SN, Mann SC. 1993. Neuroleptic, malignant syndrome. Med Clin North Am 77: 185-202.
17. Casey DE. 1985. Spontaneous tardive dyskinesia; clinical and laboratory studies. J Clin Psychiatry 46: 42-47.
18. Chakos MH, Alvir JMJ, Woemer MG, et al. 1996. Incidence and correlates of tardive dyskinesia in first episode schizophrenia. Arch Gen Psychiatry 53: 313-319.
19. Correll CU, Leucht S, Kane JM. 2004. Lower risk for tardive dyskinesia. associated with second generation antipsychotics: a systematic review of one year studies. Am J Psychiatry 161 (3): 414-425.
20. CSM. 2004. Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of medicines (CEM/ CMO/200401).
21. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (6): 553-564.
22. Day JC, Kinderman P, Bentall R. 1998. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 97 (1): 93-97.
23. Delay J, Deniker P. 1969. Drug-induced extra-pyramidal syndromes. In Handbook of Clinical Neurology. Vol. 6.- Diseases of the Basal Ganglia, Vinken PS, Bruyn GW (eds). Elsevier, North-Holland: New York; 248-266.
24. Devinsky O, Honigfeld G, Patin J. 1991. Clozapine related seizures. Neurology 41: 369-371.
25. Dunayevich E, Strakowski SM. 1999. Olanzapine-induced tardive dystonia. Am J Psychiatry 156: 662.
26. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. 2003. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96 (9): 635-642.
27. Ekblom B, Eriksson K, Lindström LH. 1984. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacol (Berl) 83 (3): 293-294.
28. Eklund K. 1987. Supersensitivity and clozapine withdrawal. Psychopharmacology 91: 135.
29. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. 2004. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65 (5): 696-701.
30. Freeman HL. 1997. Amisulpiride compared with standard neuroleptics in acute exacerbations of schizophrenia. Int Clin Psychopharmacol 120: S11-S17.
31. Geddes J, Freemantle N, Harrison P, Bebbington P. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (7273): 1371-1376.
32. Gill SS, Rochon PA, Herrmann N. et al. 2005. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Br Med J 330: 445-448.
33. Gillman PK. 1999. The serotonin syndrome and its treatment. J Psychopharmacol 13 (1): 100-109.
34. Gillman PK. 2006. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59 (11): 1046-1051.
35. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology (revised edition). US Department of Health, Education and Welfare: Washington, DC.
36. Haddad PM. 1994. Neuroleptic malignant syndrome. May be caused by other drugs. BMJ 308 (6922): 200.
37. Haddad P. 1998. The SSRI discontinuation syndrome. J Psychopharmacol 12 (3): 305-313.
38. Haddad PM. 2001. Antidepressant discontinuation syndromes. Drug Saf 24 (3): 183-197.
39. Haddad PM, Devarajan S, Dursun SM. 2001. Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'. J Psychopharmacol 15 (2): 139-141.
40. Hansen L. 2001. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 16 (7): 495-505.
41. Henriksson S, Isacsson G. 2006. Increased antidepressant use and fewer suicides in Jämtland county, Sweden, after a primary care educational programme on the treatment of depression. Acta Psychiatr Scand 114 (3): 159-167.
42. Herrmann N, Mamdani M, Lanctôt KL. 2004. Atypical Antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 161: 1113-1115.
43. Hollister LE, Eikenberry DT, Raffel S. 1960. Chlorpromazine in non-psychotic patients with pulmonary tuberculosis. Am Rev Resp Dis 81: 562-563.
44. Isbister GK, Whyte IM. 2002. Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors. Br J Anaesth 88 (4): 603.
45. Kane JM. 1999. Tardive dyskinesia in affective disorders. J Clin Psychiatry 60 (Suppl 5): 43-47, discussion 48-49.
46. Kapczinski F, Lima MS, Souza JS, Schmitt R. 2003. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003 (2): CD003592.
47. Kenney C, Hunter C, Jankovic J. 2007. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 22 (2): 193-197.
48. Leucht S, Wahlbeck K, Hamann J, Kissling W. 2003a. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (9369): 1581-1589.
49. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003b. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160 (7): 1209-1222.
50. Lewis RV, Lofthouse C. 1993. Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf 9 (4): 272-279.
51. Lieberman J, Saltz B, John C, Pollak S, Borenstein M, Kane J. 1991. The effect of clozapine in tardive dyskinesia. Br J Psychiatry 154: 503-510,
52. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
53. Liperoti R, Gambassi G, Lapane KL, et al. 2005. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 66 (9): 1090-1096.
54. Mann AM, MacPherson A. 1959. Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatr Assoc J 4: 38-47.
55. Mason PJ, Morris VA, Balcezak TJ. 2000. Serotonin syndrome. Presentation of 2 cases and review of the literature. Med (Baltimore) 79 (4): 201-209.
56. Mathews T, Aderibigbe YA. 1999. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 2 (2): 129-144.
57. Michelson D, Fava M, Amsterdam J. et al. 2000. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 176: 363-368.
58. Miller CH, Fleischhacker WW. 2000. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22 (1): 73-81.
59. Mitra S, Haddad PM. 2007. Documentation of extrapyramidal symptoms. Psychiatr Bull 31: 76-77.
60. National Institute for Clinical Excellence. 2002. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical Guideline 1. NICE: London (www.nice.org.uk).
61. National Institute for Clinical Excellence. 2004. Depression: Management of Depression in Primary and Secondary Care. Clinical Guideline 23. NICE: London; www.nice.org.uk/pdf/ CG023quickrefguide.pdf
62. Newton-John H. 1988. Acute upper airway obstruction due to supraglottic, dystonia induced by a neuroleptic. BMJ 297 (6654): 964-965.
63. Norton J. 2001. Laryngeal dystonia in psychiatry. Can J Psychiatry 46 (5): 453.
64. Oates JA, Sjostrand U. 1960. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 10: 1076-1078.
65. Olfson M, Shaffer D, Marcus SC, Greenberg T. 2003. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60 (10): 978-982.
66. Olmsted TR. 1998. Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics. South Med J 81 (7): 888-891.
67. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE, Jr. 2006. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 67 (4): 509-516.
68. Peuskens J. 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712-726.
69. Pinninti NR, Mago R, Adityanjee. 2006. Tardive dystonia-associated prescription of aripiprazole. J Neuropsychiatry Clin Neurosci 18 (3): 426-427.
70. Pope HG, Keck PE, McElroy SL. 1986. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143 (10): 1227-1233.
71. Prior TI, Baker GB. 2004. Anticholinergic toxicity (chapter 16). In Adverse Syndromes and Psychiatric Drugs, Haddad P, Dursun S, Deakin B (eds). Oxford University Press: Oxford; 293-297.
72. Reulbach U, Dütsch C, Biermann T, et al. 2007. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 110: R4.
73. Rosebush PI, Stewart TD, Gelenberg AJ. 1989. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 50 (8): 295-298.
74. Rosenbaum JF, Fava M, Hoog SL. et al. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 44: 77-87.
75. Saltz BL, Woener MG, Kane JM. et al. 1991. A prospective study of tardive dyskinesia incidence in the elderly. JAMA 66: 2402-2406.
76. Schneider LS, Dagerman KS, Insel P. 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (15): 1934-1943.
77. Schneider LS, Dagerman K, Insel PS. 2006a. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (3): 191-210.
78. Schneider LS, Tariot PN, Dagerman KS, et al. Study CATIE-AD Group. 2006b. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (15): 1525-1538.
79. Shalev A, Hermesh H, Munitz H. 1989. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 50 (1): 18-25.
80. Silins E, Copeland J, Dillon R 2007. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust N Z J Psychiatry 41 (8): 649-655.
81. Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E. 1990. Acute dystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol 10 (6): 389-396.
82. Soares-Weiser K, Fernandez HH. 2007. Tardive dysidnesia. Semin Neurol 27 (2): 159-169.
83. Sporer KA. 1995. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13 (2): 94-104.
84. Stanilla JK, de Leon J, Simpson GM. 1997. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 58 (6): 252-255.
85. Stein DJ, Ipser JC, Seedat S. 2006. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev Volume 1: CD002795.
86. Sternbach H. 1991. The serotonin syndrome. Am J Psychiatry 148: 705-713.
87. Stones M, Kennie DC, Fulton JD. 1990. Dystonic dysphagia associated with fluspirilene. BMJ. 301 (6753): 668-669.
88. Susman VL. 2001. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 72 (4): 325-336.
89. Swett C. 1975. Drug-induced dystonia. Am J Psychiatry 132 (5): 532-534.
90. Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S. 1997. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 20 (1): 90-93.
91. Tohen M, Greil W, Calabrese JR, et al. 2005. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162 (7): 1281-1290.
92. Tranter R, Healy D. 1996. Neuroleptic discontinuation syndromes. J Psychopharmacol 12: 401-406.
93. van Harten PN, Kahn RS. 1999. Tardive dystonia. Schizophr Bull 25 (4): 741-748.
94. van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG. 1999. Tardive dyskinesia in psychosis: are women really more at risk? UK700 Group. Acta Psychiatr Scand 99 (4): 288-293.
95. Vercueil L, Foucher J. 1999. Risperidone-induced tardive dystonia and psychosis. Lancet 353 (9157): 981.
96. Wang PS, Schneeweiss S, Avorn J, et al. 2005. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (22): 2335-2341.
97. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. 1987. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 144 (9): 1148-1153.
98. Youssef HA, Waddington JL. 1987. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 75 (1): 74-77.
99. Zoleptil Summary of Product Characteristics. 2002. Newbury; Orion Pharma (UK) Ltd.